Review article: management of hepatic disease following haematopoietic cell transplant (Q36555955)

14 August 2017

1 reference

title

Review article: management of hepatic disease following haematopoietic cell transplant (English)

1 reference

14 August 2017

1 reference

McDonald GB

1

1 reference

PubMed ID

16886910

14 August 2017

language of work or name

English

0 references

publication date

1 August 2006

1 reference

Alimentary Pharmacology & Therapeutics

14 August 2017

1 reference

14 August 2017

24

1 reference

14 August 2017

3

1 reference

14 August 2017

441-452

1 reference

Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation

14 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Pre-emptive use of lamivudine in bone marrow transplantation with chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

A strategy for managing fungal infections in haematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Cyclophosphamide metabolism is affected by azole antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Acalculous cholecystitis in bone marrow transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Biliary obstruction in hematopoietic cell transplant recipients: an uncommon diagnosis with specific causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with acyclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Treatment of adenovirus infections in the immunocompromised host

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Treatment of chronic hepatitis C virus in allogeneic bone marrow transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Hepatic iron concentration and total body iron stores in thalassemia major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Liver transplantation 27 years after bone marrow transplantation from the same living donor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Long-term outcome of hepatitis C infection after bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03001.X

Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance

21 January 2018

1 reference

27 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1086/422009

Identifiers

DOI

10.1111/J.1365-2036.2006.03001.X

1 reference

14 August 2017

1 reference

PubMed ID

16886910